Updates are available Correction dated 2023-06-16
Click to view Correction: https://doi.org/10.1038/s12276-023-01037-6
-
Authors
Jang, Eunji
Shin, Min-Kyue
Kim, Hyunki
Lim, Joo Yeon
Lee, Jae Eun
Park, Jungmin
Kim, Jungeun
Kim, Hyeseon
Shin, Youngmin
Son, Hye-Young
Choi, Yoon Young
Hyung, Woo Jin
Noh, Sung Hoon
Suh, Jin-Suck
Sung, Ji-Yong https://orcid.org/0000-0002-8397-1691
Huh, Yong-Min
Cheong, Jae-Ho https://orcid.org/0000-0002-1703-1781
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2018R1A5A2025079, 2017M3A9G5083322)
- License Information
-
More Information
Article History
Received: 14 September 2022
Revised: 31 December 2022
Accepted: 14 February 2023
First Online: 1 May 2023
Change Date: 16 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s12276-023-01037-6
COMPETING INTERESTS
: J.-H.C., S.H.N., J.-S.S., and Y.-M.H. are founders and shareholders of Novomics. J.-H.C. is a founder and shareholder of Veraverse. All other authors declare no competing interests.
: All clinical samples were collected after obtaining written informed consent from the patients. All animal and human studies were approved by the Institutional Review Board of YCC. All animal experiments were conducted with the approval of the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.
